ReportKeywords - Next Generation, Inhibitors, Stimulators Market, Roots Analysis,Report
Therapies targetingnovel inhibitory and stimulatory immune checkpoints have been shown to possesssubstantial therapeutic potential, both as monotherapies and in combinationwith other interventions, across multiple disease interventions
Roots Analysis is pleased toannounce the publication of its recent study, titled, “Next Generation ImmuneCheckpoint Inhibitors and Stimulators Market, 2020-2030.”
The report features an extensive study of thecurrent market landscape, offering an informed opinion on the likely adoptionof these therapies over the next decade. It features an in-depth analysis,highlighting the capabilities of various stakeholders engaged in this domain.In addition to other elements, the study includes:
§ A detailed assessmentof the current market landscape of drug developers engaged in the developmentof next generation immune checkpoint modulators.
§ A detailed analysisof more than 590 completed, ongoing and planned clinical studies of nextgeneration immune checkpoint inhibitors and stimulators.
§ Detailed profiles ofdevelopers of next generation immune checkpoint modulators (shortlistedon the basis of the number of pipeline products).
§ An in-depth analysisof more than 490 grants that have been awarded to research institutes engagedin next generation immune checkpoint therapy-related projects.
§ An analysis of thepartnerships that have been established in this domain, in the recent past.
§ A competitivenessanalysis of biological targets, featuring insightful pictorial summaries andrepresentations.
§ An analysis of the initiativesof big biopharma players engaged in this domain.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
To request for samplereport – https://www.rootsanalysis.com/reports/303/request-sample.html
- Target Disease Indication
§ Breast Cancer
§ Chronic LymphocyticLeukemia
§ Colorectal Cancer
§ Head and Neck Cancer
§ Lung Cancer
§ Lupus Nephritis
§ Melanoma
§ Multiple Myeloma
§ Primary Sjögren'sSyndrome
§ Others
- Target Immune Checkpoint
§ B7-H3
§ CD38
§ CD40
§ CD47
§ Others
- Mechanism of Action
§ Inhibitory
§ Stimulatory
- Therapeutic Modality
§ Monoclonal Antibody
§ Small Molecule
- Type of Therapy
§ Monotherapy
§ Combination Therapy
- Route of Administration
§ Intravenous
§ Subcutaneous
§ Others
- Key Geographical Region
§ North America
§ Europe
§ Asia-Pacific and theRest of the World
Keycompanies covered in the report
§ Bristol Myers Squibb
§ GlaxoSmithKline
§ Incyte
§ Novartis
§ Trillium Therapeutics
Formore information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Other Recent Offerings
1. Neoantigen TargetedTherapies Market, 2019-2030
2. Bispecific AntibodyTherapeutics Market (4th Edition), 2019-2030
3. Global Stem CellsMarket: Focus on Clinical Therapies, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastestgrowing market research companies, sharing fresh and independent perspectivesin the bio-pharmaceutical industry. The in-depth research, analysis andinsights are driven by an experienced leadership team which has gained manyyears of significant experience in this sector. If you’d like help with yourgrowing business needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
